Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04554878 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dose escalation study with Expansion Cohorts at RP2D and Schedule |
| Name | Type | Description |
|---|---|---|
| PF-04554878 | DRUG | Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging |
Inclusion Criteria: * Patients with advanced non-hematologic malignancies. * Adequate organ function, including bilirubin less than 1.5 x ULN, and ECOG (Eastern Cooperative Oncology Group) performance status of 0-2. Exclusion Criteria: * Clinically significant gastrointestinal abnormalities, requ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
PF-04554878 is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development, and it has been studied in patients with advanced non-hematologic malignancies. The drug is not yet approved and remains under investigation.
PF-04554878 is being developed by Verastem, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VSTM. The company is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
PF-04554878 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study. The drug is still investigational and has not been approved by regulatory authorities for any indication.
PF-04554878 has been studied in one completed clinical trial, identified as NCT00787033. This Phase 1 study, titled 'A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies,' enrolled 46 patients with cancer in the United States and Canada. The trial was open to adults aged 18 years and older.
PF-04554878 is the primary name for this investigational drug, and no alternative names have been reported. It is a small molecule being developed by Verastem, Inc. for oncology indications, and it is currently in Phase 1 clinical development.